Iovance Biotherapeutics Stock Buy Hold or Sell Recommendation
| IOVA Stock | USD 10.59 1.69 13.76% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Iovance Biotherapeutics is 'Strong Sell'. Macroaxis provides Iovance Biotherapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding IOVA positions.
Check out Iovance Biotherapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide. In addition, we conduct extensive research on individual companies such as Iovance and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Iovance Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Iovance |
Execute Iovance Biotherapeutics Buy or Sell Advice
The Iovance recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Iovance Biotherapeutics. Macroaxis does not own or have any residual interests in Iovance Biotherapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Iovance Biotherapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Iovance Biotherapeutics Trading Alerts and Improvement Suggestions
| Iovance Biotherapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 1.19 M. Net Loss for the year was (444.04 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Iovance Biotherapeutics currently holds about 424.46 M in cash with (361.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69. | |
| Iovance Biotherapeutics has a very weak financial position based on the latest SEC disclosures | |
| Over 87.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Iovance Biotherapeutics Inc Q3 2024 Earnings Call Highlights Surpassing Revenue ... |
Iovance Biotherapeutics Returns Distribution Density
The distribution of Iovance Biotherapeutics' historical returns is an attempt to chart the uncertainty of Iovance Biotherapeutics' future price movements. The chart of the probability distribution of Iovance Biotherapeutics daily returns describes the distribution of returns around its average expected value. We use Iovance Biotherapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Iovance Biotherapeutics returns is essential to provide solid investment advice for Iovance Biotherapeutics.
| Mean Return | 0.56 | Value At Risk | -5.87 | Potential Upside | 7.54 | Standard Deviation | 5.18 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Iovance Biotherapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Iovance Stock Institutional Investors
| Shares | Long Focus Capital Management, Llc | 2024-06-30 | 4.1 M | Principal Financial Group Inc | 2024-09-30 | 4 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 3.5 M | Jpmorgan Chase & Co | 2024-06-30 | 3.4 M | Hood River Capital Management Llc | 2024-06-30 | 2.7 M | Goldman Sachs Group Inc | 2024-06-30 | 2.6 M | Voloridge Investment Management, Llc | 2024-06-30 | 2.5 M | Mpm Oncology Impact Management Lp | 2024-06-30 | 2.4 M | Dimensional Fund Advisors, Inc. | 2024-06-30 | 2.3 M | Vanguard Group Inc | 2024-06-30 | 26 M | Perceptive Advisors Llc | 2024-06-30 | 25.9 M |
Iovance Biotherapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (62.7M) | 53.4M | 11.5M | 153.8M | (116.8M) | (111.0M) | |
| Free Cash Flow | (165.8M) | (251.9M) | (265.5M) | (313.2M) | (384.1M) | (364.9M) | |
| Depreciation | 1.2M | 1.1M | 14.0M | 21.1M | 33.1M | 34.8M | |
| Capital Expenditures | 6.9M | 46.8M | 37.6M | 20.4M | 22.3M | 23.4M | |
| Net Income | (197.6M) | (259.6M) | (342.3M) | (395.9M) | (444.0M) | (421.8M) | |
| End Period Cash Flow | 19.4M | 72.9M | 84.3M | 238.2M | 114.9M | 64.9M | |
| Other Non Cash Items | 6.6M | 7.6M | 6.0M | 871K | (3.5M) | (3.4M) | |
| Investments | 96.9M | (271.1M) | 37.7M | 256.5M | (81.9M) | (86.0M) | |
| Change To Netincome | 24.0M | 40.9M | 69.8M | 84.9M | 97.6M | 102.5M |
Iovance Biotherapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Iovance Biotherapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Iovance Biotherapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Iovance stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.24 | |
β | Beta against Dow Jones | 1.97 | |
σ | Overall volatility | 4.18 | |
Ir | Information ratio | 0.08 |
Iovance Biotherapeutics Volatility Alert
Iovance Biotherapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Iovance Biotherapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Iovance Biotherapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Iovance Biotherapeutics Fundamentals Vs Peers
Comparing Iovance Biotherapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Iovance Biotherapeutics' direct or indirect competition across all of the common fundamentals between Iovance Biotherapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Iovance Biotherapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Iovance Biotherapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Iovance Biotherapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Iovance Biotherapeutics to competition |
| Fundamentals | Iovance Biotherapeutics | Peer Average |
| Return On Equity | -0.65 | -0.31 |
| Return On Asset | -0.33 | -0.14 |
| Operating Margin | (1.52) % | (5.51) % |
| Current Valuation | 2.91 B | 16.62 B |
| Shares Outstanding | 304.78 M | 571.82 M |
| Shares Owned By Insiders | 0.52 % | 10.09 % |
| Shares Owned By Institutions | 87.14 % | 39.21 % |
| Number Of Shares Shorted | 60.34 M | 4.71 M |
| Price To Earning | (3.51) X | 28.72 X |
| Price To Book | 4.17 X | 9.51 X |
| Price To Sales | 35.51 X | 11.42 X |
| Revenue | 1.19 M | 9.43 B |
| EBITDA | (427.43 M) | 3.9 B |
| Net Income | (444.04 M) | 570.98 M |
| Cash And Equivalents | 424.46 M | 2.7 B |
| Cash Per Share | 2.69 X | 5.01 X |
| Total Debt | 75.86 M | 5.32 B |
| Debt To Equity | 0.17 % | 48.70 % |
| Current Ratio | 6.72 X | 2.16 X |
| Book Value Per Share | 2.28 X | 1.93 K |
| Cash Flow From Operations | (361.82 M) | 971.22 M |
| Short Ratio | 14.23 X | 4.00 X |
| Earnings Per Share | (1.48) X | 3.12 X |
| Target Price | 23.92 | |
| Number Of Employees | 557 | 18.84 K |
| Beta | 0.59 | -0.15 |
| Market Capitalization | 3.23 B | 19.03 B |
| Total Asset | 780.35 M | 29.47 B |
| Retained Earnings | (2.01 B) | 9.33 B |
| Working Capital | 197.54 M | 1.48 B |
| Current Asset | 290.82 M | 9.34 B |
| Current Liabilities | 10.12 M | 7.9 B |
| Net Asset | 780.35 M |
Note: Disposition of 2813 shares by Igor Bilinsky of Iovance Biotherapeutics subject to Rule 16b-3 [view details]
Iovance Biotherapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Iovance . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Iovance Biotherapeutics Buy or Sell Advice
When is the right time to buy or sell Iovance Biotherapeutics? Buying financial instruments such as Iovance Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Iovance Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Precious Metals Funds Thematic Idea Now
Precious Metals Funds
Funds or Etfs that invest in entities that are involved in mining, processing or dealing of precious metals. The Precious Metals Funds theme has 29 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Iovance Biotherapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 0.327 | Quarterly Revenue Growth 123.851 | Return On Assets (0.33) | Return On Equity (0.65) |
The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.